T
Teriparatide [Forteo]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Teriparatide
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
04/06/2025 Romosozumab and teriparatide for treating osteoporosis
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended:
Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and
Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture
due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
04/06/2025 Teriparatide biosimilar for treating osteoporosis
The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection for treatment of patients with severe established osteoporosis (T-score ≤ -3.0) with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months. The decision was based on the acceptable pricing proposal from the company.
Funding status
[R] Teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.
[NR] MAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Forteo Injection, Solution 750 mcg/3 mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
* Clinical information is available for this product.